综合考虑：在早期黑色素瘤患者的局部治疗中，将粒细胞-巨噬细胞集落刺激因子（GM-CSF）添加到CpG-B中的潜在益处。
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.
作者信息
Koster Bas D, de Jong Tamarah D, van den Hout Mari F C M, Sluijter Berbel J R, Vuylsteke Ronald J C L M, Molenkamp Barbara G, Vosslamber Saskia, van den Tol M Petrousjka, van den Eertwegh Alfons J M, de Gruijl Tanja D
机构信息
Departments of Medical Oncology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Departments of Rheumatology, Amsterdam UMC, Vrije Universiteit, Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands.
出版信息
Oncoimmunology. 2019 Dec 26;9(1):1708066. doi: 10.1080/2162402X.2019.1708066. eCollection 2020.
Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.
虽然Toll样受体9（TLR9）激动剂被认为是抗肿瘤免疫的强大刺激物，但粒细胞-巨噬细胞集落刺激因子（GM-CSF）的评价褒贬不一。在先前报道的随机试验中，我们评估了单独使用CpG-B或联合GM-CSF进行局部免疫调节对早期黑色素瘤的影响。在此，我们讨论GM-CSF的附加价值，并展示性别相关差异。
Zotero 插件